Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Description

GlobalData, the industry analysis specialist, has released its new report, Postmenopausal Osteoporosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Post Menopausal Osteoporosis Therapeutics market. The report identifies the key trends shaping and driving the global Post Menopausal Osteoporosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Post Menopausal Osteoporosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Post Menopausal Osteoporosis Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Post Menopausal Osteoporosis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Post Menopausal Osteoporosis Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Post Menopausal Osteoporosis Therapeutics therapeutics market.
• Analysis of key recent licensing and partnership agreements in Post Menopausal Osteoporosis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Post Menopausal Osteoporosis Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Post Menopausal Osteoporosis Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• Whats the next big thing in the global Post Menopausal Osteoporosis Therapeutics market landscape? Identify, understand and capitalize.

Table of Contents

1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6

2 Postmenopausal Osteoporosis Therapeutics: Introduction 7
2.1 Disease Overview 7
2.2 Epidemiology 9
2.3 Etiology 10
2.4 Pathophysiology 10
2.5 Signs and Symptoms 11
2.6 Diagnosis 11
2.6.1 Medical History 11
2.6.2 BMD Testing 12
2.6.3 Laboratory Tests 13
2.7 Treatment and Management Options 14
2.8 GlobalData Pipeline Report Guidance 16

3 Postmenopausal Osteoporosis Therapeutics: Market Characterization 17
3.1 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) Global 17
3.2 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) Global 18
3.3 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) The US 20
3.4 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) The US 21
3.5 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) France 22
3.6 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) France 23
3.7 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) Germany 24
3.8 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) Germany 25
3.9 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) Italy 26
3.10 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) Italy 27
3.11 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) Spain 28
3.12 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) Spain 29
3.13 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) The UK 30
3.14 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) The UK 31
3.15 Postmenopausal Osteoporosis Therapeutics Market Size (2005-2010) Japan 32
3.16 Postmenopausal Osteoporosis Therapeutics Market Forecast (2010-2017) Japan 33
3.17 Drivers and Barriers for the Postmenopausal Osteoporosis Therapeutics Market 34
3.17.1 Drivers for the Postmenopausal Osteoporosis Therapeutics Market 34
3.17.2 Barriers for the Postmenopausal Osteoporosis Therapeutics Market 35
3.18 Opportunity and Unmet Need Analysis 36
3.19 Key Takeaway 37

4 Postmenopausal Osteoporosis Therapeutics: Competitive Assessment 38
4.1 Overview 38
4.2 Strategic Competitor Assessment 38
4.3 Product Profiles for the Major Marketed Products in the Postmenopausal Osteoporosis Therapeutics Market 39
4.3.1 Fosamax (alendronate sodium) 39
4.3.2 Actonel (risedronate sodium) 41
4.3.3 Boniva (ibandronate sodium) 43
4.3.4 Reclast (zoledronic acid) 44
4.3.5 Evista (raloxifene hydrochloride) 45
4.3.6 Prolia (denosumab) 47
4.3.7 Forteo (teriparatide [rDNA origin]) injection 48
4.3.8 Miacalcin (salmon calcitonin) 50
4.3.9 Activella (estradiol, norethindrone acetate) 50
4.3.10 Premarin (estrogen) 52
4.3.11 Prempro (conjugated estrogens and medroxyprogesterone acetate) 52
4.4 Key Takeaway 53

5 Postmenopausal Osteoporosis Therapeutics: Pipeline Assessment 54
5.1 Overview 54
5.2 Strategic Pipeline Assessment 54
5.3 Postmenopausal Osteoporosis Therapeutics Pipeline by Phases of Development 54
5.3.1 Postmenopausal Osteoporosis Therapeutics Phase III Pipeline 55
5.3.2 Postmenopausal Osteoporosis Therapeutics Phase II Pipeline 55
5.3.3 Postmenopausal Osteoporosis Therapeutics Phase I Pipeline 55
5.3.4 Postmenopausal Osteoporosis Market Pre-Clinical Pipeline 55
5.3.5 Technology Trends Analytic Framework 56
5.4 Postmenopausal Osteoporosis Therapeutics Market Clinical Pipeline by Mechanism of Action 58
5.5 Postmenopausal Osteoporosis Therapeutics Promising Drugs Under Clinical Development 59
5.6 Molecule Profile for Promising Drugs Under Clinical Development 59
5.6.1 Odanacatib (MK-0822) 59
5.6.2 PREOS (parathyroid hormone 1-84 [rDNA origin] injection) 60
5.6.3 NB S101 60
5.6.4 SMC021 61
5.7 Key Takeaway 61

6 Postmenopausal Osteoporosis Therapeutics: Clinical Trials Mapping 62
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan) 62
6.2 Clinical Trials by Phase 63
6.3 Clinical Trials by Trial Status 64
6.4 Prominent Sponsors 65
6.5 Clinical Trials by Overall Sponsors 66
6.6 Top Companies Participating in Postmenopausal Osteoporosis Therapeutics Clinical Trials 67

7 Postmenopausal Osteoporosis Therapeutics: Strategic Assessment 68
7.1 Key Events Impacting the Future Market 68
7.2 Postmenopausal Osteoporosis Therapeutics: Implications for Future Market Competition 68

8 Postmenopausal Osteoporosis Therapeutics: Future Players 70
8.1 Introduction 70
8.2 Company Profiles 71
8.2.1 Amgen Inc. 71
8.2.2 Merck & Co., Inc. 73
8.2.3 Novartis AG 76
8.2.4 NPS Pharmaceuticals 80
8.2.5 Osteologix, Inc. 82
8.2.6 Other Companies in the Postmenopausal Osteoporosis Market 84

9 Postmenopausal Osteoporosis Therapeutics: Licensing & Partnership Deals 85

10 Postmenopausal Osteoporosis Therapeutics: Appendix 87
10.1 Market Definitions 87
10.2 Abbreviations 87
10.3 Methodology 88
10.3.1 Coverage 88
10.3.2 Secondary Research 89
10.3.3 Forecasting 89
10.3.4 Primary Research 92
10.3.5 Expert Panel Validation 92
10.4 Contact Us 92
10.5 Disclaimer 92
10.6 Bibliography 93

List of Table:

Table 1: Difference Between Type I and Type II Osteoporosis 8
Table 2: Osteoporosis Prevalence and Low Bone Mass in People Aged 50 and Over (The US) (million)* 9
Table 3: Difference Between Diagnostic Techniques Used for BMD Measurement 12
Table 4: WHO Classification for Diagnosis of Osteoporosis Using BMD Measurements 13
Table 5: Approved Drugs for the Prevention and Treatment of Postmenopausal Osteoporosis 15
Table 6: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue ($bn), 20052010 18
Table 7: Postmenopausal Osteoporosis Therapeutics Market, Global, Forecast ($bn), 20102017 19
Table 8: Postmenopausal Osteoporosis Therapeutics Market, The US, Revenue ($bn), 20052010 20
Table 9: Postmenopausal Osteoporosis Therapeutics Market, The US, Forecast ($bn), 20102017 21
Table 10: Postmenopausal Osteoporosis Therapeutics Market, France, Revenue ($m), 20052010 22
Table 11: Postmenopausal Osteoporosis Therapeutics Market, France, Forecast ($m), 20102017 23
Table 12: Postmenopausal Osteoporosis Therapeutics Market, Germany, Revenue ($m), 20052010 24
Table 13: Postmenopausal Osteoporosis Therapeutics Market, Germany, Forecast ($m), 20102017 25
Table 14: Postmenopausal Osteoporosis Therapeutics Market, Italy, Revenue ($m), 20052010 26
Table 15: Postmenopausal Osteoporosis Therapeutics Market, Italy, Forecast ($m), 20102017 27
Table 16: Postmenopausal Osteoporosis Therapeutics Market, Spain, Revenue ($m), 20052010 28
Table 17: Postmenopausal Osteoporosis Therapeutics Market, Spain, Forecast ($m), 20102017 29
Table 18: Postmenopausal Osteoporosis Therapeutics Market, The UK, Revenue ($m), 20052010 30
Table 19: Postmenopausal Osteoporosis Therapeutics Market, The UK, Forecast ($m), 20102017 31
Table 20: Postmenopausal Osteoporosis Therapeutics Market, Japan, Revenue ($m), 20052010 32
Table 21: Postmenopausal Osteoporosis Therapeutics Market, Japan, Forecast ($m), 20102017 33
Table 22: Effect of Actonel on the Risk of Vertebral Fractures 42
Table 23: Effect of Evista on Risk of Vertebral Fractures 46
Table 24: Effect of Evista on Increases in BMD vs. Placebo 47
Table 25: Effect of Forteo on Risk of Vertebral Fractures in Postmenopausal Women with Osteoporosis 49
Table 26: Mean Percentage Change in BMD in Postmenopausal Women with Osteoporosis 49
Table 27: Postmenopausal Osteoporosis Therapeutics Phase III Pipeline, 2010 55
Table 28: Postmenopausal Osteoporosis Therapeutics Phase II Pipeline, 2010 55
Table 29: Postmenopausal Osteoporosis Therapeutics Phase I Pipeline, 2010 55
Table 30: Postmenopausal Osteoporosis Therapeutics Pre-Clinical Pipeline, 2010 55
Table 31: Postmenopausal Osteoporosis Therapeutics Most Promising Drugs Under Clinical Development, 2010 59
Table 32: Postmenopausal Osteoporosis Therapeutics Market Clinical Trials by Region/ Country, 2010 62
Table 33: Postmenopausal Osteoporosis Therapeutics Clinical Trials by Phase, 2010 63
Table 34: Postmenopausal Osteoporosis Therapeutics Clinical Trials by Status, 2010 64
Table 35: Postmenopausal Osteoporosis Therapeutics Prominent Sponsors, 2010 65
Table 36: Postmenopausal Osteoporosis Therapeutics Overall Sponsors, 2010 66
Table 37: Postmenopausal Osteoporosis Therapeutics Top Companies Participating in Therapeutics Clinical Trials, 2010 67
Table 38: Amgen Inc. Deals, Alliances and Partnership 72
Table 39: Merck & Co., Inc. Deals, Alliances and Partnership 74
Table 40: Merck & Co., Inc. Womens Health Pipeline, 2010 76
Table 41: Novartis AG Deals, Alliances and Partnership 78
Table 42: Novartis AG - Womens Health Pipeline Products, 2010 79
Table 43: NPS Pharmaceuticals Deals, Alliances and Partnership 81
Table 44: NPS Pharmaceuticals Womens Health Pipeline, 2010 81
Table 45: Osteologix, Inc. Deals, Alliances and Partnership 83
Table 46: Osteologix, Inc. Womens Health Pipeline, 2010 83
Table 47: Postmenopausal Osteoporosis Therapeutics Market Future Players 84
Table 48: Postmenopausal Osteoporosis Therapeutics, Global, Deals 85

List of Charts:

Figure 1: Variation in the Levels of Bone Density with Age in Females 7
Figure 2: Classification of Osteoporosis 8
Figure 3: Postmenopausal Osteoporosis Therapeutics Market, Global, Revenue ($bn), 20052010 17
Figure 4: Postmenopausal Osteoporosis Therapeutics Market, Global, Forecast ($bn), 20102017 19
Figure 5: Postmenopausal Osteoporosis Therapeutics Market, The US, Revenue ($bn), 20052010 20
Figure 6: Postmenopausal Osteoporosis Therapeutics Market, The US, Forecast ($bn), 20102017 21
Figure 7: Postmenopausal Osteoporosis Therapeutics Market, France, Revenue ($m), 20052010 22
Figure 8: Postmenopausal Osteoporosis Therapeutics Market, France, Forecast ($m), 20102017 23
Figure 9: Postmenopausal Osteoporosis Therapeutics Market, Germany, Revenue ($m), 20052010 24
Figure 10: Postmenopausal Osteoporosis Therapeutics Market, Germany, Forecast ($m), 20102017 25
Figure 11: Postmenopausal Osteoporosis Therapeutics Market, Italy, Revenue ($m), 20052010 26
Figure 12: Postmenopausal Osteoporosis Therapeutics Market, Italy, Forecast ($m), 20102017 27
Figure 13: Postmenopausal Osteoporosis Therapeutics Market, Spain, Revenue ($m), 20052010 28
Figure 14: Postmenopausal Osteoporosis Therapeutics Market, Spain, Forecast ($m), 20102017 29
Figure 15: Postmenopausal Osteoporosis Therapeutics Market, The UK, Revenue ($m), 20052010 30
Figure 16: Postmenopausal Osteoporosis Therapeutics Market, The UK, Forecast ($m), 20102017 31
Figure 17: Postmenopausal Osteoporosis Therapeutics Market, Japan, Revenue ($m), 20052010 32
Figure 18: Postmenopausal Osteoporosis Therapeutics Market, Japan, Forecast ($m), 20102017 33
Figure 19: Opportunity and Unmet Need in the Postmenopausal Osteoporosis Therapeutics Market 36
Figure 20: Postmenopausal Osteoporosis Therapeutics Strategic Competitor Assessment, 2010 39
Figure 21: Postmenopausal Osteoporosis Therapeutics Pipeline by Phase of Development, 2010 54
Figure 22: Postmenopausal Osteoporosis Therapeutics Technology Trends Analytics Framework, 2010 56
Figure 23: Postmenopausal Osteoporosis Therapeutics Technology Trends Analytics Framework Description, 2010 57
Figure 24: Postmenopausal Osteoporosis Therapeutics Pipeline by Mechanism of Action, 2010 58
Figure 25: Postmenopausal Osteoporosis Therapeutics Clinical Trials by Country, 2010 62
Figure 26: Postmenopausal Osteoporosis Therapeutics Clinical Trials by Phase, 2010 63
Figure 27: Postmenopausal Osteoporosis Therapeutics Clinical Trials by Status, 2010 64
Figure 28: Postmenopausal Osteoporosis Therapeutics Prominent Sponsors, 2010 65
Figure 29: Postmenopausal Osteoporosis Therapeutics Overall Sponsors, 2010 66
Figure 30: Postmenopausal Osteoporosis Therapeutics Top Companies Participating in Therapeutics Clinical Trials, 2010 67
Figure 31: Postmenopausal Osteoporosis Therapeutics Market Drivers and Restraints 2010 68
Figure 32: Implications for Future Market Competition in the Postmenopausal Osteoporosis Market, 2010 68
Figure 33: Postmenopausal Osteoporosis Therapeutics Market Pipeline by Company, 2010 70
Figure 34: GlobalData Market Forecasting Model 91

More Reports in Pharmaceutical

EGIS Pharmaceuticals Plc: Pharmaceuticals and Healthcare Company Profile & SWOT Report


Blue Cross Blue Shield of Michigan: Pharmaceuticals and Healthcare Company Profile & SWOT Report


Purdue Pharma L.P.: Pharmaceuticals and Healthcare Company Profile & SWOT Report


Mitsubishi Tanabe Pharma Corporation: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Nissan Chemical Industries, Ltd.: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Eisai Co., Ltd.: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Asahi Kasei Corporation: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Perrigo Company: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Align Technology, Inc.: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report


Daiichi Sankyo Company, Ltd: Pharmaceuticals and Healthcare Company Profile, SWOT & Financial Report

By This Publisher

Ferring Pharmaceuticals, Inc. Product Pipeline Review 2012


ACADIA Pharmaceuticals Inc. Product Pipeline Review 2012


ADVENTRX Pharmaceuticals, Inc. Product Pipeline Review 2012


Anavex Life Sciences Corp. - Product Pipeline Review - 2012


Ark Therapeutics Group plc Product Pipeline Review 2012


BioMarin Pharmaceutical Inc. Product Pipeline Review 2012


Bionovo, Inc. Product Pipeline Review 2012


Boehringer Ingelheim GmbH Product Pipeline Review 2012


BTG plc Product Pipeline Review 2012


Celldex Therapeutics, Inc. Product Pipeline Review 2012